In the BioHarmony Drug Report Database

"Preview" Icon

Delafloxacin meglumine

Baxdela, Quofenix (delafloxacin meglumine) is a small molecule pharmaceutical. Delafloxacin meglumine was first approved as Baxdela on 2017-06-19. It is used to treat bacterial infections, bacterial skin diseases, escherichia coli infections, klebsiella infections, and staphylococcal infections amongst others in the USA. It has been approved in Europe to treat bacterial skin diseases. Baxdela’s patents are valid until 2033-02-27 (FDA).

 

Trade Name

 

Quofenix
 

Common Name

 

delafloxacin meglumine
 

ChEMBL ID

 

CHEMBL2105638
 

Indication

 

bacterial infections, bacterial skin diseases, escherichia coli infections, klebsiella infections, staphylococcal infections, streptococcal infections
 

Drug Class

 

Antibacterials (quinolone derivatives)

Image (chem structure or protein)

Delafloxacin meglumine structure rendering